Welsis (WLSS) EBITDA Margin (2022 - 2023)
Welsis (WLSS) posted quarterly EBITDA Margin of 613.25% for Q4 2023, down 35008.0% year-over-year from N/an in Q4 2022, and down 22277.28% quarter-over-quarter from 2.77% in Q3 2023.
Welsis (WLSS) EBITDA Margin (2022 - 2023) Analysis & Trends
Welsis' EBITDA Margin history runs 2 years deep, the most recent figure standing at 613.25% for Q4 2023.
- In Q4 2023, EBITDA Margin fell 35008.0% year-over-year to 613.25%; the TTM figure through Sep 2024 stood at 2894.9% (down 277170.0% YoY), while the FY2024 annual figure was 2894.9%, down 277493.0% from the prior year.
- EBITDA Margin for Q4 2023 stood at 613.25%, down from 2.77% in the prior quarter.
- The five-year high for EBITDA Margin was 2.77% in Q3 2023, with the low at 613.25% in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 39.72 Bn | 32.40 Bn | 662.02 Mn | 30.93% |
| 2 | BrightSpring Health Services | 12.19 Bn | 11.64 Bn | 492.75 Mn | 3.37% |
| 3 | Healthequity | 8.79 Bn | 8.52 Bn | 256.31 Mn | 29.03% |
| 4 | 10x Genomics | 7.31 Bn | 6.76 Bn | 112.50 Mn | -12.95% |
| 5 | Hinge Health | 7.10 Bn | 6.71 Bn | 183.95 Mn | 19.00% |
| 6 | MiniMed | 5.66 Bn | 5.36 Bn | 480.00 Mn | -11.11% |
| 7 | Waystar Holding | 4.76 Bn | 4.56 Bn | 221.99 Mn | 23.79% |
| 8 | Doximity | 4.46 Bn | 3.77 Bn | 132.93 Mn | 21.48% |
| 9 | Heartflow | 3.66 Bn | 3.28 Bn | 53.19 Mn | -27.93% |
| 10 | Welsis | 1.65 Mn | 1.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -613.25% |
| Sep 30, 2023 | 2.77% |
| Jun 30, 2023 | -60.64% |
| Dec 31, 2022 | -263.17% |